|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gandaglia G, Leni R, Bray F, Fleshner N,
Freedland SJ, Kibel A, Stattin P, Van Poppel H and La Vecchia C:
Epidemiology and prevention of prostate cancer. Eur Urol Oncol.
4:877–892. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Saini S: PSA and beyond: Alternative
prostate cancer biomarkers. Cell Oncol (Dordr). 39:97–106. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lavallée LT, Binette A, Witiuk K, Cnossen
S, Mallick R, Fergusson DA, Momoli F, Morash C, Cagiannos I and
Breau RH: Reducing the harm of prostate cancer screening: Repeated
prostate-specific antigen testing. Mayo Clin Proc. 91:17–22. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
De Robertis M, Poeta ML, Signori E and
Fazio VM: Current understanding and clinical utility of miRNAs
regulation of colon cancer stem cells. Semin Cancer Biol.
53:232–247. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang H, Tang Y, Yang D and Zheng L:
MicroRNA-591 functions as a tumor suppressor in hepatocellular
carcinoma by lowering drug resistance through inhibition of
far-upstream element-binding protein 2-mediated phosphoinositide
3-kinase/Akt/mammalian target of rapamycin axis. Pharmacology.
104:173–186. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li JL, Li KZ, Xie MZ, Tang YP, Tang YL and
Hu B: Clinical significance and prognostic value of miR-28-5p in
colon cancer. Dis Markers. 2020:31598312020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li M, Zhou Y, Xia T, Zhou X, Huang Z,
Zhang H, Zhu W, Ding Q and Wang S: Circulating microRNAs from the
miR-106a-363 cluster on chromosome X as novel diagnostic biomarkers
for breast cancer. Breast Cancer Res Treat. 170:257–270. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Peng L, Li S, Li Y, Wan M, Fang X, Zhao Y,
Zuo W, Long D and Xuan Y: Regulation of BTG3 by microRNA-20b-5p in
non-small cell lung cancer. Oncol Lett. 18:137–144. 2019.PubMed/NCBI
|
|
10
|
Xia L, Li F, Qiu J, Feng Z, Xu Z, Chen Z
and Sun J: Oncogenic miR-20b-5p contributes to malignant behaviors
of breast cancer stem cells by bidirectionally regulating CCND1 and
E2F1. BMC Cancer. 20:9492020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Streleckiene G, Inciuraite R, Juzenas S,
Salteniene V, Steponaitiene R, Gyvyte U, Kiudelis G, Leja M, Ruzgys
P, Satkauskas S, et al: miR-20b and miR-451a are involved in
gastric carcinogenesis through the PI3K/AKT/mTOR signaling pathway:
Data from gastric cancer patients, Cell lines and ins-gas mouse
model. Int J Mol Sci. 21:8772020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang B, Yang J and Xiao B: MicroRNA-20b
(miR-20b) promotes the proliferation, migration, invasion, and
tumorigenicity in esophageal cancer cells via the regulation of
phosphatase and tensin homologue expression. PLoS One.
11:e01641052016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Pantazis TL, Giotakis AI, Karamagkiolas S,
Giotakis I, Konstantoulakis M, Liakea A and Misiakos EP: Low
expression of miR-20b-5p indicates favorable prognosis in laryngeal
squamous cell carcinoma, especially in patients with
non-infiltrated regional lymph nodes. Am J Otolaryng.
41:1025632020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yang H, Lin J, Jiang J, Ji J, Wang C and
Zhang J: miR-20b-5p functions as tumor suppressor microRNA by
targeting cyclinD1 in colon cancer. Cell Cycle. 19:2939–2954. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hong S, Yu S, Li J, Yin Y, Liu Y, Zhang Q,
Guan H, Li Y and Xiao H: MiR-20b displays tumor-suppressor
functions in papillary thyroid carcinoma by regulating the MAPK/ERK
signaling pathway. Thyroid. 26:1733–1743. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Guo J, Xiao Z, Yu X and Cao R: miR-20b
promotes cellular proliferation and migration by directly
regulating phosphatase and tensin homolog in prostate cancer. Oncol
Lett. 14:6895–6900. 2017.PubMed/NCBI
|
|
17
|
Hoey C, Ahmed M, Fotouhi Ghiam A, Vesprini
D, Huang X, Commisso K, Commisso A, Ray J, Fokas E, Loblaw DA, et
al: Circulating miRNAs as non-invasive biomarkers to predict
aggressive prostate cancer after radical prostatectomy. J Transl
Med. 17:1732019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lu Y, Delijani K, Mecum A and Goldkorn A:
Current status of liquid biopsies for the detection and management
of prostate cancer. Cancer Manag Res. 11:5271–5291. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yang H, Zhang H, Ge S, Ning T, Bai M, Li
J, Li S, Sun W, Deng T, Zhang L, et al: RETRACTED: Exosome-derived
miR-130a activates angiogenesis in gastric cancer by targeting
C-MYB in vascular endothelial cells. Mol Ther. 26:2466–2475. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Colaprico A, Silva TC, Olsen C, Garofano
L, Cava C, Garolini D, Sabedot TS, Malta TM, Pagnotta SM,
Castiglioni I, et al: TCGAbiolinks: An R/bioconductor package for
integrative analysis of TCGA data. Nucleic Acids Res. 44:e712016.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Law CW, Chen Y, Shi W and Smyth GK: voom:
Precision weights unlock linear model analysis tools for RNA-seq
read counts. Genome Biol. 15:R292014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhao L, Jing Y, Wang J, Li H, Che J and
Cao B: Isolation and Identification of miRNAs in exosomes derived
from serum of colon cancer patients. J Cancer. 8:1145–1152. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bachurski D, Schuldner M, Nguyen PH, Malz
A, Reiners KS, Grenzi PC, Babatz F, Schauss AC, Hansen HP, Hallek M
and Pogge von Strandmann E: Extracellular vesicle measurements with
nanoparticle tracking analysis-an accuracy and repeatability
comparison between NanoSight NS300 and ZetaView. J Extracell
Vesicles. 8:15960162019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chen Y and Wang X: miRDB: An online
database for prediction of functional microRNA targets. Nucleic
Acids Res. 48:D127–D131. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dweep H and Gretz N: miRWalk2.0: A
comprehensive atlas of microRNA-target interactions. Nat Methods.
12:6972015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gene Ontology Consortium, . Gene ontology
consortium: Going forward. Nucleic Acids Res. 43:D1049–D1056. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yu G, Wang LG, Han Y and He QY:
clusterProfiler: An R package for comparing biological themes among
gene clusters. OMICS. 16:284–287. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chandrashekar DS, Bashel B, Balasubramanya
SA, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BV and Varambally
S: UALCAN: A portal for facilitating tumor subgroup gene expression
and survival analyses. Neoplasia. 19:649–658. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Vasaikar SV, Peter S, Wang J and Zhang B:
LinkedOmics: Analyzing multi-omics data within and across 32 cancer
types. Nucleic Acids Res. 46:D956–D963. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tutrone R, Donovan MJ, Torkler P,
Tadigotla V, McLain T, Noerholm M, Skog J and Mckiernan J: Clinical
utility of the exosome based ExoDx prostate(IntelliScore) EPI test
in men presenting for initial biopsy with a PSA 2–10 ng/ml.
Prostate Cancer Prostatic Dis. 23:607–614. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Fujita K and Nonomura N: Urinary
biomarkers of prostate cancer. Int J Urol. 25:770–779. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhu Q, Cheng L, Deng C, Huang L, Li J,
Wang Y, Li M, Yang Q, Dong X, Su J, et al: The genetic source
tracking of human urinary exosomes. Proc Natl Acad Sci USA.
118:e21088761182021. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kowlessur B, Phull M, Patel B, Henry M and
Lazarus J: Validating the European randomised study for screening
of prostate cancer (ERSPC) risk calculator in a contemporary South
African cohort. World J Urol. 38:1711–1718. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yu J, Chen S, Niu Y, Liu M, Zhang J, Yang
Z, Gao P, Wang W, Han X and Sun G: Functional significance and
therapeutic potential of miRNA-20b-5p in esophageal squamous cell
carcinoma. Mol Ther Nucleic Acids. 21:315–331. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Xue TM, Tao LD, Zhang M, Xu GC, Zhang J
and Zhang PJ: miR-20b overexpression is predictive of poor
prognosis in gastric cancer. Onco Targets Ther. 8:1871–1876. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Schitcu VH, Raduly L, Nutu A, Zanoaga O,
Ciocan C, Munteanu VC, Cojocneanu R, Petrut B, Coman I, Braicu C
and Berindan-Neagoe I: MicroRNA dysregulation in prostate cancer.
Pharmgenomics Pers Med. 15:177–193. 2022.PubMed/NCBI
|
|
38
|
Dyson NJ: RB1: A prototype tumor
suppressor and an enigma. Gene Dev. 30:1492–1502. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Aparicio AM, Shen L, Tapia EL, Lu JF, Chen
HC, Zhang J, Wu G, Wang X, Troncoso P, Corn P, et al: Combined
tumor suppressor defects characterize clinically defined aggressive
variant prostate cancers. Clin Cancer Res. 22:1520–1530. 2016.
View Article : Google Scholar : PubMed/NCBI
|
